Table 22.
HCC prediction models using LS measurement by VCTE
| Model | Region | Etiology | Study number | Risk factors |
AUC | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age | Sex | HBV DNA | HBeAg | ALT | Serum albumin | Platelet count | Cirrhosis in USG | Spleen size | VCTE | |||||
| LS [461] | Korea | HBV | 1,250 | O | O | O | O | 0.81 | ||||||
| LSM-HCC [439] | Hong Kong | HBV | 1,555 | O | O | O | O | 0.83–0.89 | ||||||
| LSPS [462] | Korea | HBV | 227 | O | O | O | 0.83 | |||||||
| mREACH-B [465] | Korea | HBV (complete VR) | 192 | O | O | O | O | O | 0.81 | |||||
| CAMPAS [463] | Korea | HBV (VR) | 1,511 | O | O | O | O | O | O | 0.87 | ||||
| mPAGELS-B [467] | Korea | HBV (AVT) | 2,184 | O | O | O | O | 0.76 | ||||||
| SAGE-B [464] | Europe | HBV (5-year post-AVT) | 734 | O | O | 0.78–0.80 | ||||||||
| Alonso López et al. [428] | Spain | HCV (SVR after DAA) | 1,046 | O | O | 0.78 | ||||||||
| Lee et al. [468] | Korea | NAFLD | 3,133 | O | O | O | 0.94–0.95 | |||||||
ALT, alanine aminotransferase; AVT, antiviral therapy; AUC, area under the curve; DAA, direct acting antiviral; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; LS, liver stiffness; SVR, sustained virologic response; USG, ultrasonography; VCTE, vibration-controlled transient elastography; VR, virologic response.